 |
Vol.63 No.6 contents | Japanese/English |
 | Full Text of PDF (759K) Article in Japanese |
- Case Report -
A Case of Lung Adenocarcinoma Harboring EGFR Mutation with a Severe Decreased Ejection Fraction After the Administration of Osimertinib
Hiroto Watanabe1, Yoshihito Kogure1, Masahide Oki11Department of Respiratory Medicine, National Hospital Organization Nagoya Medical Center, Japan
Background. Osimertinib, which is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has shown significant efficacy in EGFR mutation-positive non-small cell lung cancer. Case. The patient was a 76-year-old man who was diagnosed with lung adenocarcinoma (T2aN3M0, stage IIIB), EGFR exon 19 deletion in December 2020. The patient received osimertinib from January 2021. He developed dyspnea from February 2021. He was diagnosed with heart failure and received azosemide in April 2021. His dyspnea worsened from July 2021, and he was admitted to the cardiology department in August 2021. Heart failure improved with the administration of vasopressor and diuretics. After his discharge from the hospital, osimertinib was changed to gefitinib. His heart failure and lung cancer have not worsened since the change. Conclusion. If signs of heart failure are observed during treatment with osimertinib, the discontinuation of treatment or drug modification should be considered immediately.
key words: Lung adenocarcinoma, EGFR-TKI, Osimertinib, Ejection fraction decreased
Received: April 6, 2023
Accepted: June 2, 2023
JJLC 63 (6): 864-868, 2023
